Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai,

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study.

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

How to Treat MDS without Stem Cell Transplantation

Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are.

Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program John P. Miller, Elizabeth H. Perry, Thomas H.

Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program’s.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Pain, Donation-Related Symptoms and the Trajectory of Recovery in Children after Bone Marrow (BM) Donation Are Influenced By Age (Pre vs. Post-Puberty)

Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program Chatchada Karanes,

Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptoms and Less Complete Rates of Recovery Compared to Unrelated Donors:

Sabina Kersting, Leo F. Verdonck

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Access to Hematopoietic Cell Transplantation in the United States

Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR Gregory.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Navneet S. Majhail, Elizabeth A. Murphy, Nancy A

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation K. Scott Baker, Stella M. Davies, Navneet S. Majhail,

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Relationship of Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients James L. Gajewski, Mark.

Frederick R. Appelbaum, Claudio Anasetti, Joseph H

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

High-Resolution Match Rate of 7/8 and 9/10 or Better for the Be The Match Unrelated Donor Registry Kelly Buck, Kim Wadsworth, Michelle Setterholm, Martin.

Analysis of Hematopoietic Cell Transplants Using Plasma-Depleted Cord Blood Products That Are Not Red Blood Cell Reduced Robert Chow, Auayporn Nademanee,

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Biology of Blood and Marrow Transplantation

Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902.

Life Satisfaction in Young Adults 10 or More Years after Hematopoietic Stem Cell Transplantation for Childhood Malignant and Nonmalignant Diseases Does.

Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor– Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a.

Steven M. Trifilio, Judy Pi, Jayesh Mehta

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

HLA-Mismatched, Noninherited Maternal Antigen–Matched Unrelated Cord Blood Transplantations Have Superior Survival: How HLA Typing the Cord Blood Donor's.

Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery Navneet S. Majhail, Lih-Wen Mau,

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Karen K. Ballen, Roberta J. King, Pintip Chitphakdithai, Charles D

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence Fausto R. Loberiza, Stephanie.

Transplantation of Unrelated Donor Umbilical Cord Blood for Nonmalignant Diseases: a Single Institution's Experience with 45 Patients Tang-Her Jaing,

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Optimal Donor Selection: Beyond HLA

Presentation transcript:

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai, Brent Logan, Roberta King, Steven Devine, Susan N. Rossmann, Gregory Hale, Robert J. Hartzman, Chatchada Karanes, Ginna G. Laport, Eneida Nemecek, Edward L. Snyder, Galen E. Switzer, John Miller, Willis Navarro, Dennis L. Confer, John E. Levine Biology of Blood and Marrow Transplantation Volume 21, Issue 1, Pages 142-150 (January 2015) DOI: 10.1016/j.bbmt.2014.10.001 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Overall survival at 3 years for (A) age <18 years, malignant diseases, (B) age 18 to 59 years, malignant diseases, (C) age ≥ 60 years, malignant diseases, and (D) nonmalignant diseases. Biology of Blood and Marrow Transplantation 2015 21, 142-150DOI: (10.1016/j.bbmt.2014.10.001) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions